What is Polaryx Therapeutics, Inc.'s earnings per share (EPS)?

Polaryx Therapeutics, Inc. (PLYX) reported diluted earnings per share of $-0.20 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Polaryx Therapeutics, Inc. Financials

PLYX

Source SEC Filings (10-K/10-Q) Updated Mar 23, 2026 Currency USD FYE March

This page shows Polaryx Therapeutics, Inc. (PLYX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.44x

For every $1 of reported earnings, Polaryx Therapeutics, Inc. generates $0.44 in operating cash flow (-$3.9M OCF vs -$9.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$9.0M

Polaryx Therapeutics, Inc. reported -$9.0M in net income in fiscal year 2025.

EPS (Diluted)

$-0.20

Polaryx Therapeutics, Inc. earned $-0.20 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$5.1M

Polaryx Therapeutics, Inc. held $5.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

47M

Polaryx Therapeutics, Inc. had 47M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-196.8%

Polaryx Therapeutics, Inc.'s ROE was -196.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$6.3M

Polaryx Therapeutics, Inc. invested $6.3M in research and development in fiscal year 2025.

Share Buybacks

N/A

Capital Expenditures

N/A

PLYX Income Statement

Metric	FY25
Revenue	N/A
Cost of Revenue	N/A
Gross Profit	N/A
R&D Expenses	$6.3M
SG&A Expenses	$1.6M
Operating Income	-$7.8M
Interest Expense	N/A
Income Tax	N/A
Net Income	-$9.0M
EPS (Diluted)	$-0.20

PLYX Balance Sheet

Metric	FY25
Total Assets	$5.2M
Current Assets	$5.2M
Cash & Equivalents	$5.1M
Inventory	N/A
Accounts Receivable	N/A
Goodwill	N/A
Total Liabilities	$605K
Current Liabilities	$605K
Long-Term Debt	N/A
Total Equity	$4.6M
Retained Earnings	-$99.6M

PLYX Cash Flow Statement

Metric	FY25
Operating Cash Flow	-$3.9M
Capital Expenditures	N/A
Free Cash Flow	N/A
Investing Cash Flow	N/A
Financing Cash Flow	$4.5M
Dividends Paid	N/A
Share Buybacks	N/A

PLYX Financial Ratios

Metric	FY25
Gross Margin	N/A
Operating Margin	N/A
Net Margin	N/A
Return on Equity	-196.8%
Return on Assets	-173.8%
Current Ratio	8.55
Debt-to-Equity	0.13
FCF Margin	N/A

Frequently Asked Questions

Is Polaryx Therapeutics, Inc. profitable?

No, Polaryx Therapeutics, Inc. (PLYX) reported a net income of -$9.0M in fiscal year 2025.

What is Polaryx Therapeutics, Inc.'s return on equity (ROE)?

Polaryx Therapeutics, Inc. (PLYX) has a return on equity of -196.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Polaryx Therapeutics, Inc.'s operating cash flow?

Polaryx Therapeutics, Inc. (PLYX) generated -$3.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Polaryx Therapeutics, Inc.'s total assets?

Polaryx Therapeutics, Inc. (PLYX) had $5.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Polaryx Therapeutics, Inc. spend on research and development?

Polaryx Therapeutics, Inc. (PLYX) invested $6.3M in research and development during fiscal year 2025.

How many shares does Polaryx Therapeutics, Inc. have outstanding?

Polaryx Therapeutics, Inc. (PLYX) had 47M shares outstanding as of fiscal year 2025.

What is Polaryx Therapeutics, Inc.'s current ratio?

Polaryx Therapeutics, Inc. (PLYX) had a current ratio of 8.55 as of fiscal year 2025, which is generally considered healthy.

What is Polaryx Therapeutics, Inc.'s debt-to-equity ratio?

Polaryx Therapeutics, Inc. (PLYX) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Polaryx Therapeutics, Inc.'s return on assets (ROA)?

Polaryx Therapeutics, Inc. (PLYX) had a return on assets of -173.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Polaryx Therapeutics, Inc.'s cash runway?

Based on fiscal year 2025 data, Polaryx Therapeutics, Inc. (PLYX) had $5.1M in cash against an annual operating cash burn of $3.9M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are Polaryx Therapeutics, Inc.'s earnings high quality?

Polaryx Therapeutics, Inc. (PLYX) has an earnings quality ratio of 0.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.